Shingrix vaccine study for people with rheumatic immune diseases
Part of Bones, joints & muscles, Infections, Skin clinical trials.
This trial tests whether Shingrix (a shingles vaccine) is safe and works well in adults with rheumatic or immune-related conditions. It compares Shingrix to a placebo (inactive shot) to see how well it prevents shingles and affects immune symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 years or older)
- You have a rheumatic or immune-mediated disease (like lupus, rheumatoid arthritis, psoriatic arthritis, vasculitis, or similar)
- Your immune-suppressing medicines are stable or being reduced, and started/changed recently as allowed by the study
- If you could become pregnant, you must use effective birth control from before vaccination until at least 12 months after the shots
- You’re willing and able to follow all study visits and procedures
- You can sign consent in writing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new shingles vaccine to see if it's safe and helps the body build immunity. It is for healthy adults aged 50 and older who have not had shingles before.
This study tests a new shingles vaccine for people 40 and older. It looks at safety, how well the body responds, and whether it can prevent shingles.
This trial tests a new shingles vaccine in healthy adults aged 50 to 65. Shingles can cause a painful rash, and the vaccine aims to prevent it.
This Phase 1/2 study tests how safe and how well a shingles (varicella zoster) vaccine works in adults living with HIV whose immune status is measured by CD4 count, plus a healthy comparison group. It may help researchers understand whether the vaccine can safely boost protection in people with HIV.
This trial tests a new shingles vaccine to see how well it prevents shingles in adults aged 40 and older. It aims to help those who have not had shingles recently or been vaccinated against it before.
This study tests an experimental shingles vaccine in adults aged 40 and older. It aims to see if the vaccine is safe and helps your body build immunity against shingles.
Hear when a new Herpes Zoster trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.